Primecap Management Co. CA Acquires 32,942 Shares of LivaNova PLC $LIVN

Primecap Management Co. CA increased its stake in LivaNova PLC (NASDAQ:LIVN) by 0.7% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 4,641,352 shares of the company’s stock after purchasing an additional 32,942 shares during the quarter. Primecap Management Co. CA owned approximately 0.09% of LivaNova worth $208,954,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. LSV Asset Management increased its position in LivaNova by 22.7% in the second quarter. LSV Asset Management now owns 538,010 shares of the company’s stock worth $24,221,000 after buying an additional 99,512 shares in the last quarter. Ontario Teachers Pension Plan Board purchased a new stake in LivaNova in the 2nd quarter worth approximately $3,029,000. Creative Planning bought a new stake in LivaNova during the 2nd quarter worth approximately $1,123,000. SG Americas Securities LLC raised its stake in LivaNova by 4,082.6% during the 2nd quarter. SG Americas Securities LLC now owns 202,144 shares of the company’s stock worth $9,101,000 after acquiring an additional 197,311 shares during the period. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its holdings in LivaNova by 7.9% during the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 14,009 shares of the company’s stock valued at $631,000 after purchasing an additional 1,029 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

LivaNova Stock Performance

LIVN opened at $53.89 on Wednesday. The stock has a market capitalization of $2.94 billion, a price-to-earnings ratio of -13.85 and a beta of 1.00. LivaNova PLC has a fifty-two week low of $32.48 and a fifty-two week high of $58.91. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.09 and a current ratio of 1.29. The company has a fifty day moving average of $53.52 and a 200 day moving average of $49.25.

LivaNova (NASDAQ:LIVN) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $1.11 earnings per share for the quarter, beating analysts’ consensus estimates of $0.91 by $0.20. LivaNova had a positive return on equity of 14.57% and a negative net margin of 16.13%.The firm had revenue of $357.80 million during the quarter, compared to analyst estimates of $342.32 million. During the same quarter last year, the business posted $0.90 earnings per share. The business’s quarterly revenue was up 12.5% compared to the same quarter last year. LivaNova has set its FY 2025 guidance at 3.800-3.90 EPS. As a group, sell-side analysts forecast that LivaNova PLC will post 2.85 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently commented on LIVN shares. Mizuho raised their price objective on shares of LivaNova from $65.00 to $70.00 and gave the company an “outperform” rating in a research report on Thursday, November 13th. Wall Street Zen upgraded LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 9th. Barclays raised their price target on LivaNova from $55.00 to $58.00 and gave the company an “equal weight” rating in a report on Thursday, August 21st. Weiss Ratings restated a “sell (d-)” rating on shares of LivaNova in a research report on Wednesday, October 8th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $64.00 price objective on shares of LivaNova in a research note on Wednesday, September 3rd. Five analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, LivaNova has an average rating of “Moderate Buy” and an average price target of $62.43.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.